ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Condition: Neurological Cancer Intervention: Drug: ASTX727 Sponsors: Massachusetts General Hospital; Astex Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Hospitals | Neurology | Research